Sutro BiopharmavsUnitedHealth

STRO and UNH stock compared: price, dividend, valuation and results, from SEC filings.

STRO

Sutro Biopharma, Inc.

$9.82

Value $163M

+2.40%
STRO's page

UNH

UnitedHealth Group Incorporated

$407.46

Value $370B

+0.58%
UNH's page

Sutro Biopharma (STRO) has a market value of $163M and UnitedHealth (UNH) $370B. Over the last year, with dividends, STRO moved +21.2% and UNH +23.4%. Dividend yield: STRO none, UNH 2.22%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    STRO$163M

    UNH$370B

    UNH is 2,269 times STRO

  • Revenue, 12 months

    STRO$45M

    UNH$450B

    UNH is 9,969 times STRO

  • Net income, 12 months

    STRO-$155M

    UNH$15.9B

  • Operating margin

    STRO-265.0%

    UNH5.3%

    270.3 points apart

  • ROIC

    STRO–

    UNH11.3%

  • P/E

    STRO–

    UNH23.3

  • Dividend yield

    STRO0.0%

    UNH2.2%

    2.2 points apart

  • 5-year return

    STRO-95.0%

    UNH-2.8%

    92.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

STRO-95.0%

UNH-2.8%

05010015020222023202420252026
Returns by period
PeriodSTROWith dividendsUNHWith dividends
1 year since November 12, 2025+21.2%Price +21.2%+23.4%Price +20.2%
3 years since November 13, 2023-52.6%-22.0% a yearPrice -52.6%-20.0%-7.2% a yearPrice -24.9%
5 years since November 12, 2021-95.0%-45.0% a yearPrice -95.0%-2.8%-0.6% a yearPrice -11.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

STROSutro BiopharmaUNHUnitedHealth

Valuation

STROUNH
Valuation
Price$9.82$407.46
Market value$163M$370B
Enterprise value (EV)$21M$416B
P/E–23.3
P/E, 5-year median–25.0
P/B–3.6
EV/EBIT–17.4
Free cash flow yield–6.2%

Results and growth

STROUNH
Results and growth
Revenue, 12 months$45M$450B
Net income, 12 months-$155M$15.9B
Free cash flow, 12 months–$22.8B
Earnings per share, 12 months-$12.63$17.52
Revenue growth, year on year65.2%11.8%
Revenue growth a year, past+19.1%over 5 years+11.7%over 5 years
EPS growth a year, past–-3.8%over 5 years

Margins and returns on capital

STROUNH
Margins and returns on capital
Gross margin–88.3%
Operating margin-265.0%5.3%
Net margin-344.2%3.5%
ROIC–11.3%
ROE–15.5%

Balance sheet

STROUNH
Balance sheet
Cash$142M$28.5B
Total debt$9.7M$74.3B
Net debt / EBITDA–1.6
Interest cover–6.2×

Dividends and buybacks

STROUNH
Dividends and buybacks
Dividend yield–2.2%
Dividend per share, 12 months–$9.06
Dividend growth a year, past–+12.6%over 5 years
Buyback yield–1.5%
Shareholder yield–3.7%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: STRO or UNH

Didn't find what you were looking for?

Ask us
Which is bigger, Sutro Biopharma or UnitedHealth?

By market value, UnitedHealth ($370B) is about 2,268.6 times Sutro Biopharma ($163M), at today's prices.

How did STRO and UNH stock do over the last 5 years?

Since November 12, 2021, STRO's price moved -95.0% and UNH's -11.2%. With dividends: STRO -95.0% (-45.0% a year), UNH -2.8% (-0.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, STRO or UNH?

The dividend yield at today's price is none for Sutro Biopharma and 2.22% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.

Which has the higher profit margins, Sutro Biopharma or UnitedHealth?

Over the last twelve months, the net margin was -344.2% for Sutro Biopharma and 3.5% for UnitedHealth, and the operating margin -265.0% and 5.3%. Revenue was $45M and $450B.

Which is the better investment, Sutro Biopharma or UnitedHealth?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.